Protagonist Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Protagonist Therapeutics serves customers worldwide.

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Protagonist Therapeutics (PTGX US)

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-09-17)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)